AUTHORS
Arvin Eslami, MD, Dasom (Caroline) Lee, MD2, Masooma Shifa Rana, MBBS3, Alexandria Jensen, Phd4, Ishan Paranjpe, MD5, Shaya Alimoghadam, MD6, Eric Heng7, Humza Khan, MBBS8, Mateusz Firchal9, Francisco Cortina, BS10, Neha Taneja11, Anmol Goyal, MD12, Jayasindhu Mallampet13, Betty Chang14, Theresa Latchford15, Bita Sahaf, PhD16, Snehit Prabhu, PhD17, Amelia Scheck18, William Lee Wang, Medical Student19, Zinaida Good, PhD20, Sally Arai, MD21, Hany Elmariah, MD,MS22, Laura Johnston, MD23, Vanessa E Kennedy, MD24, Robert Lowsky, MD25, Lekha Mikkilineni, MD, MA26, Lori Muffly, MD27, Robert Negrin, MD28, Andrew Rezvani, MD29, Judith Anne Shizuru, MD, PhD30, Surbhi Sidana, MD31, Wen-Kai Weng, MD, PhD32, Sushma Bharadwaj, MD33, Melody Smith, MD,MS34, Mathew J. Frank, MD, PhD35, David Miklos, MD, PhD36, Saurabh Dahiya, MD, FACP37
AFFILIATIONS
1 Stanford University School of Medicine, Stanford, California, United States, Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 University of Nebraska Medical Center, Omaha, Nebraska, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 Stanford University School of Medicine, Stanford, California, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 Stanford University School of Medicine, Stanford, California, United States
8 AdventHealth Central Florida, Orlando, Florida, United States
9 Stanford Health Care, Stanford, California, United States
10 Stanford University School of Medicine, Stanford, California, United States
11 Stanford University School of Medicine, Stanford, California, United States
12 Cleveland Clinic, Cleveland, California, United States
13 Stanford University School of Medicine, Stanford, California, United States
14 Stanford University School of Medicine, Stanford, California, United States
15 Stanford Health Care, Stanford, California, United States
16 Stanford University School of Medicine, Stanford, California, United States
17 Stanford University School of Medicine, Stanford, California, United States
18 Stanford University School of Medicine, Stanford, California, United States
19 Stanford University School of Medicine, Stanford, California, United States
20 Stanford University School of Medicine, Stanford, California, United States
21 Stanford University School of Medicine, Stanford, California, United States
22 Stanford University School of Medicine, Stanford, California, United States
23 Stanford University School of Medicine, Stanford, California, United States
24 Stanford University School of Medicine, Stanford, California, United States
25 Stanford University School of Medicine, Stanford, California, United States
26 Stanford University School of Medicine, Stanford, California, United States
27 Stanford University School of Medicine, Stanford, California, United States
28 Stanford University School of Medicine, Stanford, California, United States
29 Stanford University School of Medicine, Stanford, California, United States
30 Stanford University School of Medicine, Stanford, California, United States
31 Stanford University School of Medicine, Stanford, California, United States
32 Stanford University School of Medicine, Stanford, California, United States
33 Stanford University School of Medicine, Stanford, California, United States
34 Stanford University School of Medicine, Stanford, California, United States
35 Stanford University School of Medicine, Stanford, California, United States
36 Stanford University School of Medicine, Stanford, California, United States
37 Stanford University School of Medicine, Stanford, California, United States
ABSTRACT
Background
ZUMA-7 (Locke, NEJM 2022) and TRANSFORM (Kamdar, Lancet 2022) established axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for relapsed or refractory large B-cell lymphoma (r/rLBCL). Cross-trial comparisons suggest more favorable progression-free survival (PFS) with 2L than with third-line or later (3L+) CAR T-cell (CAR-T) therapy. However, real-world consortia-level data (Wang JS, Blood Adv 2026) showed similar 2L and 3L outcomes, and CAR-T expansion by line remains uncharacterized. Here, we report a single-center study evaluating the safety, effectiveness, and CAR-T expansion following 2L versus 3L+ CAR T in patients (pts) with r/rLBCL.
Methods
Pts with r/rLBCL who received CAR-T at our institution between January 1, 2018, and February 28, 2026, were retrospectively identified and categorized by lines of therapy as 2L or 3L+. Pts receiving holding therapy (HT) (one cycle of intermediary therapy between progression and leukapheresis without response evaluation) were included in the 2L cohort. Responses were assessed per Lugano 2014 criteria. Cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded by ASTCT consensus criteria and managed per institutional guidelines (Wang WL, Blood Adv 2026). Immune effector cell-associated hematotoxicity (ICAHT) was graded per EHA/EBMT consensus criteria (Rejeski, Blood 2023). PFS and overall survival (OS) were estimated by Kaplan-Meier methods and evaluated using multivariable Cox models adjusted for age, relapsed vs refractory status, ECOG, stage, LDH/ULN ratio (LDHr), cell of origin, and double/triple-hit status. Late hematologic recovery and immune reconstitution were assessed at months (mo) 3-48. Absolute CAR-T count was measured by flow cytometry at days (d) 7, 14, 21, and 28 post-infusion (Hamilton, Blood Adv 2024).
Results
The study included 471 pts (2L, n=187; 3L+, n=284), with an overall median age of 67 years (y) (r,17–89y). Baseline characteristics, including LDHr, and bridging therapy use, were similar between cohorts except for greater liso-cel use (21% vs 7%; P=0.0015) and older median age (68 vs 64y; P=0.016) in the 2L cohort. In the 3L+ cohort, 76.1% received third-line CAR-T (fourth-sixth line in the remainder). Among 2L pts, 30% received HT.
Median follow-up was 25.0 mo (IQR:15.0-35.9) and 50.7 mo (IQR:33.4-69.0) in the 2L and 3L+ cohort, respectively. Best overall response rates were 89.3% and 85.2% (P=0.17), and best complete response rates were 77.5% vs. 70.8% (P=0.096) in the 2L and 3L+ cohorts, respectively. Median PFS was not reached in the 2L cohort and was 12.9 mo (95% CI, 7.1-25.4) in 3L+ cohort (P=0.0052). Median OS was 74.6 mo (95% CI, 74.6-NA) and 43.4 mo (95% CI, 30.2-81.8) in the 2L cohort and 3L+ cohort, respectively (P=0.021). At 12 mo and 24 mo, PFS was higher in the 2L cohort vs 3L+ (62.3% vs 51.4%, P=0.020; 56.9% vs 44.5%, P=0.012). OS differed only at 24 mo (71.9% vs 60.8%; P=0.018), not at 12 mo (78.3% vs 73.7%; P=0.261). After multivariable adjustment, 3L+ therapy remained associated with inferior PFS (HR, 1.39; 95% CI, 1.05-1.84; P=0.023) and OS (HR, 1.41; 95% CI, 1.00-1.98; P=0.048). Any-grade (gr) CRS was similar in the 2L and 3L+ cohorts (86.1% vs 89.1%; P=0.40), as was any-gr ICANS (55.6% vs 48.6%; P=0.16).
Early any-gr neutropenic ICAHT was more frequent after 3L+ CAR T (31.5% vs 17.9%; P=0.002). Through 24 mo, gr 3-4 late ICAHT was more frequent in 3L+ than 2L pts for both neutropenia (16/284 [5.6%] vs 3/187 [1.6%]; P=0.032) and thrombocytopenia (8/284 [2.8%] vs 0/187 [0%]; P=0.025). At 12 mo, 3L+ recipients had numerically higher rates of CD4<200 cells/µL (45.1% vs 35.6%; P=0.20), IgG<400 mg/dL (37.5% vs 27.7%; P=0.17), and B-cell recovery at 12 months (43.4% vs 37.8%; P=0.45).
Among 275 pts with available CAR-T expansion data, median peak absolute CAR-T count was 37.84 (IQR:7.42-343.75) cells/µL in the 2L cohort (n=92) and 45.20 (IQR:7.66-892.51) cells/µL in 3L+ (n=183; P=0.395). Median AUC0-28 was 695.45 cells/µL×d (IQR:148.96-6381.05) in the 2L cohort (n=54) and 639.07 cells/µL×d (IQR:118.75-10543.16) in 3L+ (n=137; P=0.67).
Conclusion
2L CAR-T was associated with superior PFS and OS compared with 3L+ CAR-T, including after multivariable adjustment. CRS and ICANS were comparable, whereas 3L+ pts experienced greater early and late hematologic toxicity. These real-world data support the use of CAR-T at first relapse in r/rLBCL.
DISCLOSURES
Arvin Eslami, MD: No relevant conflicts of interest to declare.